Radical Gastrectomy: Still the Gold Standard Treatment for Gastric Cancer—Our Experience from a Tertiary Care Center from Northeast India
- 4 Downloads
Gastric cancer (GC) is common in the northeast and southern parts of India. Radical surgery is the cornerstone of treatment and offers the only chance for cure. This study was conducted to assess the outcomes of all resectable gastric cancers that presented to our tertiary cancer center in Northeast India. All patients undergoing upfront surgery for gastric cancer with curative intention between 2012 and 2017 were included in the study. A total of 116 patients who underwent upfront radical gastrectomy were included in the study. Males (58.6%) were more common than females (41.4%). Mean age at presentation was 56.12 years (range 26–89). The most common mode of presentation was pain abdomen (53.8%). The most common location of tumor was the distal part (81%) followed by the proximal part (10.3%). The most commonly done procedure was distal radical gastrectomy (56.9%) followed by subtotal gastrectomy (32.8%). Median number of lymph nodes isolated was 14. Fifty-four patients received adjuvant chemotherapy while 32 patients received adjuvant chemoradiation (CTRT). At a median follow-up of 14 months (range, 2–78 months), overall 5-year survival was 23.75% (mean survival 33.77 months, median survival 24 months). The 5-year survival for stages I–III was 100%, 26.25%, and 11.25%, respectively (P < 0.001). Though perioperative chemotherapy has a role in gastric cancer, it is not the substitute for radical D2 gastrectomy which is still the gold standard treatment especially in high-volume centers.
KeywordsMAGIC trial D2 lymph node dissection Perioperative chemotherapy ACCORD 07 trial Gastrectomy
- 4.GLOBOCAN Cancer fact sheets: stomach cancers [Internet]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp.
- 5.Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde C, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20CrossRefGoogle Scholar
- 6.Shrikhande SV, Barreto SG, Talole SD et al. (2013) “D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy,” World J Surg Oncol, vol. 11, article no. 31Google Scholar
- 8.Vasilescu C, Herlea V, Tidor S, Ivanov B, Stănciulea O, Mănuc M, Gheorghe C, Ionescu M, Diculescu M, Popescu I (2006) D2 lymph node dissection in gastric cancer surgery: long term results—analysis of an experience with 227 patients. Chirurgia (Bucur) 101:375–384Google Scholar
- 11.Shrikhande SV, Barreto SG, Talole SD, Vinchurkar K, Annaiah S, Suradkar K et al (2013) D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol 2:11–31Google Scholar
- 15.Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L, Italian Gastrointestinal Tumor Study Group (1999) Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Ann Surg 230(2):170–178. https://doi.org/10.1097/00000658-199908000-00006 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721CrossRefGoogle Scholar